Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis.

To determine whether microcrystalline hydroxyapatite compound (MCHC) could reduce bone loss or its consequences in patients with chronic active hepatitis (CAH) on corticosteroid therapy, a controlled trial was conducted in 36 such patients over a period of 2 years. Both skeletal symptoms (back pain)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Stellon, A., Davies, A., Webb, A., Williams, R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Group 1985
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2418401/
https://ncbi.nlm.nih.gov/pubmed/2997764
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge